Bencard Adjuvant Systems is a division of Allergy Therapeutics PLC, a fully integrated, speciality global pharmaceutical company. Allergy Therapeutics PLC is listed on the London Stock Exchange; AIM ticker AGY.

Bencard Adjuvant Systems specialise in developing and optimising adjuvants for infectious diseases, cancer immunotherapy and allergen immunotherapy.

We at Bencard Adjuvant Systems are committed to engaging in long-term partnerships with those who require our patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development.

In addition to providing novel and efficacious adjuvant platforms, Bencard Adjuvant Systems have over 70 years of experience in GMP manufacturing, QC testing, regulatory filing and compliance. Whatever your project, we can build better medicines together!

Bencard Adjuvant Systems has an adjuvant portfolio that considers optimal immunogenicity and clinical relevance of immune responses.

Our adjuvant technologies are readily adaptable and offer optimal flexibility. Our people have a wealth of intellect to help you develop the best vaccines for efficacy and safety.